TUMORI JOURNAL, THE INSTITUTIONAL JOURNAL OF FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI, COVERS ALL ASPECTS OF CANCER SCIENCE AND CLINICAL PRACTICE WITH A STRONG FOCUS ON PREVENTION AND TRANSLATIONAL MEDICINE

Tumorijournal.com

Editor in Chief: Giancarlo Pruneri ISSN: 0300-8916 - e-ISSN: 2038-2529 Frequency: 6 issues per year Impact Factor: 2.438 
The journal was completely renewed, establishing a new editorial board, creating a new graphic design, restoring the publisher, and replacing the old title in Tumori Journal (TJ). 
•    International reviewers panel: 63% from Europe, 27% from USA/Canada, 10% from ROW 
•    Altmetrics data availaible for all articles 
•    Wide visibility in international libraries/data aggregators/document delivery services 
•    Indexed in all major databases 
•    Section Editors median age = 42 
•    Section Editors H-Index = 18.5 

Affililiations 
Organisation of European Cancer Institutes (O E C I ); Italian Association of Medical Oncology (AIOM); Italian Association of Radiation Oncology (AIRO); Italian Cancer Society (SIC); Italian Society of Surgical Oncology (SICO); Italian Paediatric Hematology Oncology Association (AIEOP).

The Scientific Report 2018 - Executive summary takes into consideration the assessment carried out by the Scientific Directorate at the end of the 2017-2018 period. This new publication provides available research outputs for the year 2018 including the new strategic directions towards 4 novel research priorities – 
-    Primary prevention, secondary prevention and early diagnosis, 
-    Precision medicine and technological innovation (pharmacological and non), 
-    Complexity and rare tumors, 
-    Effectiveness Studies and “Outcome Research”. 

Scientific production in 2018 has shown an upward trend according to all the indicators conventionally used to classify and evaluate research activity: 667 clinical studies were conducted in 2018, with an increase in the number of patients included in clinical trials and protocols of research. In 2018 we published 722 scientific articles with total IF 5220.2. In this year INT has also increased its weight and authority both internationally, investing in the creation of a network of relations with the main European cancer centers, such as Cancer Core Europe (CCE) and Organization of European Cancer Institues (OECI), both nationally, intensifying its commitment to networks of excellence such as the Alliance Against Cancer, the Rare Cancer Network and the Hematology Network of Lombardy.

These outstanding results have been possible thanks to the synergic commitment of the Presidency, the General Directorate and the strong effort of all researchers, clinicians and the administrative staff.

Giovanni Apolone
Scientific Director